FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102488634> ?p ?o ?g. }

• W2102488634 endingPage "223" @default.
• W2102488634 startingPage "217" @default.
• W2102488634 abstract "Oxytocin, the gold-standard treatment for post-partum haemorrhage, needs refrigeration, intravenous infusion, and skilled providers for optimum use. Misoprostol, a potential alternative, is increasingly used ad hoc for treatment of post-partum haemorrhage; however, evidence is insufficient to lend support to recommendations for its use. This trial established whether sublingual misoprostol is non-inferior to intravenous oxytocin for treatment of post-partum haemorrhage in women receiving prophylactic oxytocin.In this double-blind, non-inferiority trial, 31 055 women exposed to prophylactic oxytocin had blood loss measured after vaginal delivery at five hospitals in Burkina Faso, Egypt, Turkey, and Vietnam (two secondary-level and three tertiary-level facilities). 809 (3%) women were diagnosed with post-partum haemorrhage and were randomly assigned to receive 800 mug misoprostol (n=407) or 40 IU intravenous oxytocin (n=402). Providers and women were masked to treatment assignment. Primary endpoints were cessation of active bleeding within 20 min and additional blood loss of 300 mL or more after treatment. Clinical equivalence of misoprostol would be accepted if the upper bound of the 97.5% CI fell below the predefined non-inferiority margin of 6%. All outcomes were assessed from the time of initial treatment. This study is registered with ClinicalTrials.gov, number NCT00116350.All randomly assigned participants were analysed. Active bleeding was controlled within 20 min after initial treatment for 363 (89%) women given misoprostol and 360 (90%) given oxytocin (relative risk [RR] 0.99, 95% CI 0.95-1.04; crude difference 0.4%, 95% CI -3.9 to 4.6). Additional blood loss of 300 mL or greater after treatment occurred for 139 (34%) women receiving misoprostol and 123 (31%) receiving oxytocin (RR 1.12, 95% CI 0.92-1.37). Shivering (152 [37%] vs 59 [15%]; RR 2.54, 95% CI 1.95-3.32) and fever (88 [22%] vs 59 [15%]; 1.47, 1.09-1.99) were significantly more common with misoprostol than with oxytocin. Six women had hysterectomies and two women died.Misoprostol is clinically equivalent to oxytocin when used to stop excessive post-partum bleeding suspected to be due to uterine atony in women who have received oxytocin prophylactically during the third stage of labour." @default.
• W2102488634 created "2016-06-24" @default.
• W2102488634 creator A5011001346 @default.
• W2102488634 creator A5011182065 @default.
• W2102488634 creator A5018285680 @default.
• W2102488634 creator A5027659387 @default.
• W2102488634 creator A5030972671 @default.
• W2102488634 creator A5041522613 @default.
• W2102488634 creator A5053713150 @default.
• W2102488634 creator A5075391732 @default.
• W2102488634 creator A5080202005 @default.
• W2102488634 creator A5086131873 @default.
• W2102488634 creator A5089047586 @default.
• W2102488634 creator A5090190096 @default.
• W2102488634 date "2010-01-01" @default.
• W2102488634 modified "2023-09-29" @default.
• W2102488634 title "Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial" @default.
• W2102488634 cites W1749423047 @default.
• W2102488634 cites W1972130051 @default.
• W2102488634 cites W1989741569 @default.
• W2102488634 cites W2010669624 @default.
• W2102488634 cites W2016410402 @default.
• W2102488634 cites W2029710559 @default.
• W2102488634 cites W2035677318 @default.
• W2102488634 cites W2068175922 @default.
• W2102488634 cites W2098972122 @default.
• W2102488634 cites W2101751442 @default.
• W2102488634 cites W2102190795 @default.
• W2102488634 cites W2102698323 @default.
• W2102488634 cites W2108931471 @default.
• W2102488634 cites W2122322088 @default.
• W2102488634 cites W2123730276 @default.
• W2102488634 cites W2147581820 @default.
• W2102488634 cites W2161872135 @default.
• W2102488634 cites W2170856832 @default.
• W2102488634 cites W2186657631 @default.
• W2102488634 cites W4235891895 @default.
• W2102488634 cites W4250116679 @default.
• W2102488634 doi "https://doi.org/10.1016/s0140-6736(09)61923-1" @default.
• W2102488634 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20060162" @default.
• W2102488634 hasPublicationYear "2010" @default.
• W2102488634 type Work @default.
• W2102488634 sameAs 2102488634 @default.
• W2102488634 citedByCount "109" @default.
• W2102488634 countsByYear W21024886342012 @default.
• W2102488634 countsByYear W21024886342013 @default.
• W2102488634 countsByYear W21024886342014 @default.
• W2102488634 countsByYear W21024886342015 @default.
• W2102488634 countsByYear W21024886342016 @default.
• W2102488634 countsByYear W21024886342017 @default.
• W2102488634 countsByYear W21024886342018 @default.
• W2102488634 countsByYear W21024886342019 @default.
• W2102488634 countsByYear W21024886342020 @default.
• W2102488634 countsByYear W21024886342021 @default.
• W2102488634 countsByYear W21024886342022 @default.
• W2102488634 countsByYear W21024886342023 @default.
• W2102488634 crossrefType "journal-article" @default.
• W2102488634 hasAuthorship W2102488634A5011001346 @default.
• W2102488634 hasAuthorship W2102488634A5011182065 @default.
• W2102488634 hasAuthorship W2102488634A5018285680 @default.
• W2102488634 hasAuthorship W2102488634A5027659387 @default.
• W2102488634 hasAuthorship W2102488634A5030972671 @default.
• W2102488634 hasAuthorship W2102488634A5041522613 @default.
• W2102488634 hasAuthorship W2102488634A5053713150 @default.
• W2102488634 hasAuthorship W2102488634A5075391732 @default.
• W2102488634 hasAuthorship W2102488634A5080202005 @default.
• W2102488634 hasAuthorship W2102488634A5086131873 @default.
• W2102488634 hasAuthorship W2102488634A5089047586 @default.
• W2102488634 hasAuthorship W2102488634A5090190096 @default.
• W2102488634 hasConcept C126322002 @default.
• W2102488634 hasConcept C131872663 @default.
• W2102488634 hasConcept C141071460 @default.
• W2102488634 hasConcept C168563851 @default.
• W2102488634 hasConcept C2776176026 @default.
• W2102488634 hasConcept C2778642596 @default.
• W2102488634 hasConcept C2779199973 @default.
• W2102488634 hasConcept C2779234561 @default.
• W2102488634 hasConcept C3017863008 @default.
• W2102488634 hasConcept C42219234 @default.
• W2102488634 hasConcept C44249647 @default.
• W2102488634 hasConcept C54355233 @default.
• W2102488634 hasConcept C71924100 @default.
• W2102488634 hasConcept C82789193 @default.
• W2102488634 hasConcept C86803240 @default.
• W2102488634 hasConceptScore W2102488634C126322002 @default.
• W2102488634 hasConceptScore W2102488634C131872663 @default.
• W2102488634 hasConceptScore W2102488634C141071460 @default.
• W2102488634 hasConceptScore W2102488634C168563851 @default.
• W2102488634 hasConceptScore W2102488634C2776176026 @default.
• W2102488634 hasConceptScore W2102488634C2778642596 @default.
• W2102488634 hasConceptScore W2102488634C2779199973 @default.
• W2102488634 hasConceptScore W2102488634C2779234561 @default.
• W2102488634 hasConceptScore W2102488634C3017863008 @default.
• W2102488634 hasConceptScore W2102488634C42219234 @default.
• W2102488634 hasConceptScore W2102488634C44249647 @default.
• W2102488634 hasConceptScore W2102488634C54355233 @default.
• W2102488634 hasConceptScore W2102488634C71924100 @default.
• W2102488634 hasConceptScore W2102488634C82789193 @default.

• next